CD80 and neoplasm: CTLA-4 inhibition by monoclonal antibodies may induce tumor rejection through direct blockade of CTLA-4 competition for CD-80 (B7-1) and CD-86 (B7-2) ligands, which enhances CD28 co-stimulation.